DALLAS and NEW YORK, June 28 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. The conference is being held at the Roosevelt Hotel in New York City.
Davis will provide an overview of Access' clinical development programs and update investors on commercialization launch activities for its lead product, MuGard - a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Access Pharmaceuticals, Inc. is gearing up for the North American commercial launch set for late summer.
A live webcast of the presentation can be accessed at the specified time by clicking on the following link: http://www.onemedplace.com/forum/webcast.php.
For information on the One Med Forum 2010, visit: http://www.onemedplace.com/forum/.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations ---------------- --------------------------- Christine Berni Donald C. Weinberger/Diana Bittner (media) Director of Investor Relations Wolfe Axelrod Weinberger Assoc. LLC Access Pharmaceuticals, Inc. (212) 370-4500 (212) 786-6208
SOURCE Access Pharmaceuticals, Inc.